All In Biotech

Drug Trial Radar · NCT07334249

First-In-Human (FIH), Single Ascending Dose (SAD) Study and Multiple Ascending Dose (MAD) Study of SP-101 Injection

A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of SP-101 Injection Following Single and Multiple Intravenous Doses in Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Dec 23, 2025

Primary completion

Jun 30, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this First-In-Human (FIH) trial is to learn about safety, tolerability and pharmacokinetics of single and multiple ascending doses of SP-101 in healthy adult volunteers.

Conditions

  • Major Depressive Disorder, Healthy Volunteer

Interventions

  • SP-101 injectionDrug

    SP-101 is non-competitive antagonist against NMDA receptor and is administered by intravenous infusion.

  • PlaceboDrug

    Participants will be randomly assigned to the experimental group and placebo groups at ratio of 3:1. Participants assigned to the experimental group will be administered SP-101 by intravenous infusion. Accordingly, participants assigned to the placebo group will be administered placebo by intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Emergent Adverse Events, throughout study completionTime frame: Through study completion, an average of 10 days for SAD and an average of 28 days for MAD

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Mental Health Center (SMHC)

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.